Adhera Therapeutics, Inc.

Equities

ATRX

US00687E4061

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 20:57:42 28/06/2024 BST			5-day change	1st Jan Change
0.017 ^USD	+143.90%		+174.19%	-43.33%

01-18	Adhera Therapeutics, Inc. Receives Written Notice from Melior Pharmaceuticals II, LLC of Election to Terminate the License Agreement	CI
01-16	Adhera Therapeutics, Inc. Announces the Resignation of Zahed Subhan as Chief Executive Officer	CI

Adhera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 22, 2023 at 08:13 pm

Adhera Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 0.886 million compared to USD 0.074 million a year ago. Basic loss per share from continuing operations was USD 0.29 compared to USD 0.51 a year ago.

Latest news about Adhera Therapeutics, Inc.

Adhera Therapeutics, Inc. Receives Written Notice from Melior Pharmaceuticals II, LLC of Election to Terminate the License Agreement	01-18	CI
Adhera Therapeutics, Inc. Announces the Resignation of Zahed Subhan as Chief Executive Officer	01-16	CI
Adhera Therapeutics, Inc. Announces Board Resignations	01-16	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-20	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21/08/23	CI
Adhera Therapeutics, Inc. announced that it has received $0.105 million in funding	21/06/23	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	22/05/23	CI
Adhera Therapeutics, Inc. announced that it has received $0.1 million in funding	27/04/23	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
Adhera Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	30/03/23	CI
Adhera Therapeutics, Inc. announced that it has received $0.214285 million in funding	01/03/23	CI
Adhera Therapeutics, Inc. announced that it has received $0.364285 million in funding	15/02/23	CI
Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes	25/01/23	CI
Adhera Therapeutics, Inc. announced that it has received $0.1 million in funding	14/12/22	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Adhera Therapeutics, Inc. Elects Zahed Subhan as Chairman of the Board	19/09/22	CI
Adhera Therapeutics, Inc. Announces CEO Changes, Effective September 30, 2022	09/09/22	CI
Adhera Therapeutics, Inc. Appoints Andrew Kucharchuk as Chief Operating Officer, Effective September 30, 2022	09/09/22	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI
Adhera Therapeutics, Inc. enter into letter of intent to acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin from Bio Innovation Group.	18/07/22	CI
Adhera Therapeutics, Inc. Planning to Initiate A Phase 2 Clinical Trial of Mlr-1023 as new Treatment for Type 1 Diabetes	19/05/22	CI
Adhera Therapeutics, Inc. Appoints Trond K. Waerness as Chairman of the Board	19/05/22	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	15/04/22	CI
Adhera Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	14/04/22	CI

Chart Adhera Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Adhera Therapeutics, Inc. is a specialty biotech company. The Company is focused on the drug development and commercialization of small molecule drugs to treat Parkinson's disease (PD) and Type 1 diabetes. The Company's advanced development programs are MLR-1019, a small molecule drug candidate being developed for PD, and MLR-1023, being developed to treat Type 1 diabetes. MLR-1019 is a highly selective dopamine re-uptake inhibitor for treating the dyskinesias associated with chronic dopamine precursor levodopa (L-DOPA) treatment in PD patients. MLR-1019 is a highly selective dopamine reuptake transporter (DAT) inhibitor used for the treatment of type 1 diabetes, non-alcoholic steatohepatitis, and pulmonary inflammation. It utilizes a virtual drug development model, where contract research organizations (CROs) are employed to undertake certain drug discovery and development services on the Companyâs behalf and under its direct supervision.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ADHERA THERAPEUTICS, INC.	-43.33%	198K
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.03%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B

Bio Therapeutic Drugs